This clinical trial is for men and women with relapsed or refractory (return of disease after treatment) multiple myeloma.
The purpose of this study is to see if an experimental drug called ISB 1442 is safe, how much ISB 1442 should be given, how it moves through the body, and how effective it is. Experimental means that ISB 1442 is not yet approved by the U.S. Food and Drug Administration (FDA).
All study participants will need to attend regularly scheduled visits with the study doctor where they will receive the study drug and have other procedures or assessments. The study team will discuss the number of visits required with each individual participant.
Participation is expected to last between 3 to 6 months or longer depending on how the body and disease responds to treatment.
Detailed eligibility will be reviewed when you contact the study team.